Caladrius Biosciences

18 articles with Caladrius Biosciences

• Caladrius Biosciences to Present at the 13th Annual LD Micro Main Event Conference

  12/9/2020

  Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announced that David J. Mazzo, PhD, the Company’s President and CEO, will be presenting at the 13th annual LD Micro Main Event investor conference on Monday, December 14, 2020 at 10:20 AM Eastern Time.

• Caladrius Biosciences Provides Corporate Update and Reports 2020 Third Quarter Financial ResultsConference call begins today at 4:30 p.m. Eastern time

  11/5/2020

  Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides a corporate update and reports financial results for the three and nine months ended September 30, 2020.

• Caladrius Biosciences Announces the Resignation of Joseph Talamo, Chief Financial Officer

  8/5/2020

  Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not simply manage, disease, announced that Joseph Talamo, Chief Financial Officer, has tendered his resignation in order to explore opportunities outside of Caladrius. To ensure a smooth transition, Mr. Talamo plans to continue to serve as CFO until August 21, 2020.

• Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

  5/26/2020

  Caladrius Biosciences, Inc. announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 2,084,850 shares of its common stock, at a purchase price of $2.0625 per share, in a registered direct offering priced at-the-market under Nasdaq rules.

• Caladrius Biosciences Reports Positive Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions

  5/14/2020

  Single administration of CLBS16 durably improves heart function and symptoms in patients with coronary microvascular dysfunction

• Caladrius Biosciences Provides Corporate Update and Reports 2020 First Quarter Financial Results

  5/7/2020

  Company initiates development of CLBS119 for the repair of COVID-19 induced lung damage and expands its proprietary CD34+ cell therapy portfolio

• Caladrius Biosciences Plans to Assess its CLBS119 Cell Therapy for Repair of COVID-19 Induced Lung Damage

  4/23/2020

  FDA authorizes new IND for the study of CLBS119 in COVID-19 patients who experienced respiratory failure

• Caladrius Biosciences to Receive $10.9 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program

  4/22/2020

  Caladrius Biosciences, Inc., announced that it has finalized an agreement to sell $10.9 million in New Jersey net operating losses to a qualifying and approved buyer pursuant to the New Jersey Economic Development Authority ’s Technology Business Tax Certificate Transfer Program.

• Caladrius Biosciences to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call on Thursday, March 5, 2020 at 4:30 p.m. Eastern Time

  2/27/2020

  Caladrius Biosciences, Inc., a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced that it will report financial results for the three and twelve months ended December 31, 2019 after the close of the U.S. financial markets on Thursday, March 5, 2020.

• Caladrius Biosciences to Participate at Upcoming February 2020 Conferences

  2/3/2020

  Caladrius Biosciences, Inc., a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced that David J. Mazzo, PhD, President and Chief Executive Officer of the Caladrius, will present a company overview at the following conferences in February:.

• Caladrius Biosciences to Participate at Upcoming January 2020 Conferences

  1/7/2020

  Caladrius Biosciences, Inc. announced that the Company will present at the following conferences in January

• Caladrius Biosciences to Participate at Upcoming December Conferences

  12/2/2019

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today that the Company will present at the following conferences in December:

• 

  Clinical Catch-Up: November 18-22

  11/25/2019

  As usual, it was a busy week for clinical trial updates. Here’s a look.

• Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019

  11/16/2019

  Single administration of CLBS16 durably improves heart function and symptoms with no cell-related adverse events

• Caladrius Biosciences Reports 2019 Third Quarter and Nine Month Financial Results and Provides Corporate UpdateConference call begins today at 4:30 p.m. Eastern time

  11/6/2019

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announces financial results for the three and nine months ended September 30, 2019. 

• Caladrius Biosciences to Participate at Upcoming November 2019 Conferences

  10/31/2019

  Caladrius Biosciences, Inc., a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced that the Company will participate in the following conferences in November

• Caladrius Biosciences to Host 2019 Third Quarter Financial Results and Business Update Conference Call on Wednesday, November 6, 2019 at 4:30 p.m. Eastern Time

  10/30/2019

  Caladrius Biosciences, Inc. announces that the Company will release financial results for the three and nine months ended September 30, 2019 after close of the U.S. financial markets on Wednesday, November 6, 2019.

• Caladrius Biosciences Reports 2017 Third Quarter Results

  11/10/2017

  Conference call begins today at 4:30 p.m. Eastern Time.